LGALS3 and metabolic dysfunction-associated steatohepatitis: The complex carbohydrate belapectin targets Galectin-3 [318] but in the NASH-CX phase 2b clinical trial (NCT02462967) did not have a significant effect on inflammation and fibrosis compared to placebo.